Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence
of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and …

Caroline Gordon1, 2, 3, Maame-Boatemaa Amissah-Arthur1, Mary Gayed1, 3, Sue Brown4,
Ian N. Bruce5, 6, David D'Cruz7, Benjamin Empson8, Bridget Griffiths9, David Jayne10, 11 …

The objective was to develop evidence-based recommendations for the management of
antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature …

The aim of this updated guideline is to provide comprehensive and timely evidence-based
recommendations on the prevention of future stroke among survivors of ischemic stroke or …

Background Rivaroxaban is established for the treatment and secondary prevention of
venous thromboembolism, but whether it is useful in patients with antiphospholipid …

Objectives To develop recommendations for the management of adult and paediatric lupus
nephritis (LN). Methods The available evidence was systematically reviewed using the …

Clarity and guidance is required with regard to the use of direct oral anticoagulants in
antiphospholipid syndrome (APS) patients, within the confines of the recent European …

Thrombotic antiphospholipid syndrome (TAPS) is characterized by venous, arterial, or
microvascular thrombosis. Patients with TAPS merit indefinite anticoagulation, and warfarin …

The antiphospholipid syndrome (APS) is defined by the occurrence of venous and arterial
thromboses, often multiple, and recurrent fetal losses, frequently accompanied by a …

The current treatment approach for systemic lupus erythematosus (SLE), as outlined in the
recommendations by international medical associations including EULAR and the ACR, is …